Prof. Dr. Friedrich Metzger is Chief Executive Officer and Co-Founder at Versameb AG. Metzger, a scientist and co-founder of Versameb, has a long track record in Pharma R&D. Under his leadership as Head of Discovery Rare Diseases at Roche, a team of scientists and project leaders managed a portfolio of highly innovative development programs. He led preclinical activities for Risdiplam, an investigational medicine for spinal muscular atrophy which is currently in the market approval process. Previously, he championed a growth factor program from initiation into clinic, as well as multiple other discovery projects in neurological and neuromuscular diseases. Friedrich is also Professor in Neurobiology at the University of Freiburg, Germany, and holds a PhD degree in pharmacology from the University of Tübingen, Germany. Versameb AG is a company that develops optimized mRNA therapies through ist VERSagile mRNA platform. VERSAMEB’s vision is to harness mRNA to help the body heal itself. He is also member of the scientific advisory board for Skyhawk Therapeutics, a company developing small molecules targeting RNA, and further consult for patient organisations in the area of rare diseases and regenerative medicine.